Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Xbrane Biopharma, Webcast with teleconference, Q2'24

By Inderes8/28/2024, 11:00 AM
Xbrane Biopharma

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Martin
00:01 - 18:36

Hello and welcome to today's webcast on the second quarter 2024 financial report of Ex Brain Biopharma. Uh, my name is Martin. I'm the CEO and I also have our CFO, Annette Lindquist, with me today. We will go through a brief presentation highlighting the operational advances during the past quarter and also the financials. And we will take questions thereafter. You can ask questions both via audio and also via the chat. Uh, and we'll do our best to answer them. Um, so let's start off here. Most of you who are calling in probably know what we are engaged in. We are biosimilar developers. So, we're developing biosimilar drugs to be approved as replacements for biologics, which can be launched post-patent expiration or loss of exclusivity of the respective originator products. Our portfolio consists of four biosimilars and biosimilar candidates. Ximluci is approved as a biosimilar to Lucentis in Europe and has been launched since the first quarter of 2003 by our commercialization partner, Strada. We are going through a regulatory process with the FDA for US approval, and we have partnered up with Valorem Biologics to commercialize the product in the US post-approval. We are developing biosimilar candidates for CMC and Opdivo, respectively, both of which are in the late pre-clinical stage. We have scaled up the respective production processes, and we are currently engaged in a very active licensing process to find a suitable commercialization partner for these two biosimilar candidates so that we, together with a partner, can proceed into clinical development. Then we have the early preclinical development of a biosimilar candidate for Dorzalex. All in all, this portfolio is addressing a market based on the originator's peak sales estimate combined of €26 billion. So we're looking at the seamless integration said Lucy Forester. We can take a snapshot of the retinal anti-VEGF market outside of the US for retinal disorders. So, this is a market of about, um, a little bit north of €5 billion in annual net sales. You can see in the graph on the left-hand side, the light blue bars represent Lucentis, the originator product, which is a biosimilar. The red bars, advancing on top, are the Lucentis biosimilars approved in Europe. We are observing that biosimilars are gradually gaining market share, which, for those of you who have followed us, has taken more time than we initially anticipated. However, we are seeing movement in the right direction with the gradual market share gain of the Lucentis biosimilars. We remain steadfast in our view. At the initiation of this development, we believed that, at the end of the day, these biosimilars would take approximately 70% volume market share of the overall randomized market. And to clarify, the active ingredient in Lucentis is called Ranibizumab. Over a couple of years, that's what we've seen for biosimilars that have entered in relation to other molecules or biological drugs, particularly in the oncology and immunology space. So, that's still the outlook we believe in. Of course, we believe that the exclusive shall be a preferred choice among respective biosimilars to Lucentis, and taking a snapshot of where we stand together with our partners when it comes to the commercialization process. Christmas is now celebrated across 18 countries. So, there's a gradual launch in additional countries. As you can see, from a value market share perspective, we're well above 1% now. This is a quarterly market, if you only look at the retinal anti-VEGF market. Lucentis plus the Lucentis biosimilars have about €300 million in quarterly sales. And this is now for the second quarter of 2024. It seamlessly took well above 1% of that market. And also ranks as the second among the Lucentis biosimilars. It's up against biosimilars commercialized by Novartis and Roche, respectively. As I said, Ximluci is number two. We're happy to note that the net sales of Ximluci showed strong growth in the second quarter, close to 40%, in net sales versus the first quarter of 2024. We're happy to see that this was partly driven by continued volume growth, as you can see in the graph. On the bottom side, on the right-hand side here, that's kind of depicting the volume growth quarter by quarter in the last quarter. We've been between 20 to 30% in volume growth. There was a 21% volume growth in the second quarter of 2024 versus the first quarter of 2024, but the 40% growth in net sales. So that, of course, included a mixed effect which impacted the average selling price positively. And that is stronger growth in markets where the price is a bit higher than in other markets, essentially. So we're happy to see that development. And we are working relentlessly together with our partners to ensure the successful continued commercialization of this product in Europe. And continue the development exclusively. As you might recall, we unfortunately received a complete response letter from the FDA on our initial biologics license application. And that was in April this year. We held a longer webcast in relation to that complete response letter. It mainly centered around issues with the reference standard, which we planned to use for the release of the product for the US market, as well as observations in pre-approval inspections done by the FDA at the respective manufacturing sites. Where the product is planned to be produced for the US market. We are now going through a process of qualifying a new reference standard, we've had a meeting with the FDA on that topic and agreed on a strategy. And exactly how we're going to ensure full alignment with the agency around the qualification of the new reference standard. And we are also working together with our respective contract manufacturers to resolve the observations which they had on their respective sites and, as previously communicated, we're targeting a resubmission of the biologics license application in the fourth quarter of this year. It's a standard six months review process for a resubmitted biologics license application. So we're expecting a decision date in the second quarter of 2025. We're also working, as you know, on the prefilled syringe of Ximluci to be launched initially in Europe. And we hope, of course, that this preferred syringe can subsequently be introduced to the US market. But initially it's about the European market and we're preparing for submission. This essentially represents a variation to the existing approval for provider authorization, of course. A launch in Europe in 2025, as you know, is currently approved and commercialized as a vial. Whereas the originator, Lucentis, by and large, is sold with a prefilled syringe. The two presentations are prevalent on the market. However, the prefilled syringe is the predominant form. There is a certain time-saving benefit in clinics, which makes the prefilled syringe the more convenient choice for ophthalmologists. Therefore, we do believe that the introduction of the prefilled syringe will unlock further market opportunities and lead to an upswing in sales across Europe. That's our expectation. So, that was briefly about Ximluci, and moving on to our biosimilar candidate CMC. It's now called Exp 003. Here we worked during the second quarter and the summer months on scaling up the production process on the drug substance side with our selected contract manufacturer, and we can happily announce that we've been successful in that. We have now successfully scaled up the production process to a suitable scale to enter clinical development. We have confirmed the analytical similarity to the reference product in the same manner as we did at the small scale, as you may have noted if you followed us over the summer. Unfortunately, we regained the rights to this program from Bayer, and we had a partnership a few years back with Bayer around this product. They underwent a strategic review of their full portfolio, and several circumstances on their end led to their decision to terminate this license agreement with us, and hence the full rights to this program have been returned to us. Immediately after receiving that notice from Bayer, we started the licensing process to find a suitable commercialization partner for the program to support us in the upcoming clinical development. We have engaged an advisory firm in this effort, and we're working with the same life science advisory firm, both when it comes to licensing of Exp 003, as well as the Xtrain biosimilar candidate. We had, prior to the termination of the agreement with Bayer, received quite a lot of incoming interest around this program. We believe it's a unique program as it's one of only a few biosimilars under development globally. Moreover, it's still a sizable originator product with approximately €2 billion in annual sales. We believe we have a unique proposition when it comes to providing this at what we believe are commercially viable production costs, thanks to our platform technology. This gives us high productivity in the production process of this specific molecule. I think we have continued strong interest in this licensing process. We are running on a tight timeline. We are trying to conclude a license agreement before the end of October. This goes both for Series three as well as Xtrain. What we are also focused on now is incorporating into the program the development activities which were previously under Bayer's responsibility, which basically involves preparing for upcoming scientific advice with the EMA and FDA to agree on the clinical development plan as well as the drug product side of the whole development. These are also areas where we expect that the future commercialization partner will support us. In any case, the program is prepared for and ready to go into the clinic in 2025. So, just briefly on item 003. Um, and sorry if we move here to, um, Ximluci, our, um, Opdivo biosimilar candidate. As noticed, these two programs are proceeding pretty much in parallel right now. We have also successfully scaled up the production process together with the selected contract manufacturer and confirmed the analytical similarity profile versus the reference product. We also, as we communicated in a press release not long ago, received positive feedback from the EMA and in the scientific advice we had with them. We essentially got an acceptance on our proposed clinical development plan, which entailed a streamlined approach. And we believe this is crucial, actually, in order to be successful with this program. As those of you who follow this market know, what is currently required from a regulatory guideline perspective is to conduct both a Phase One and a Phase Three trial for biosimilar candidates. In these trials, you compare pharmacokinetics in the Phase One, and the biosimilar versus the reference product on a well-selected efficacy endpoint in a Phase Three trial. Now, for this particular program, and this also applies if you're developing a biosimilar for Keytruda, the clinical development is much more expensive than for other biosimilar candidates. Due to its focus on oncology, we're conducting clinical trials. Generally, it's more expensive, due primarily to the very high cost of the reference product. Since we need to procure the reference product for the comparator arm in these trials, it becomes very expensive. There have been budgets allocated for Phase one and Phase three trials. All in all, there are about €120 million of very significant clinical investments behind these programs. Now, with this positive feedback from the EMA on a more streamlined approach, we see an opportunity to reduce the clinical development budget by at least half. And, uh, I think we've opened up for a lot of new interest in this program. And, we're also running an active licensing process. Um, and we're again running on a tight timeline, but we believe we will be able to uphold it. And the ambition here is to close something by the end of October. Ximluci is set to be ready to enter clinical trials in 2025. So that's a brief, kind of operational update. So, with that said, I'm going to hand over to Annette to go through the financials of the quarter.

Annette Lindquist
18:37 - 25:32

Thank you very much, Mohsin, and welcome to the final section. So, we'll start by having a look at the revenue alongside other factors. So, the first slide, and those of you who have been with us for a while, you know that our revenue stream is somewhat complicated. That's driven by accounting regulations like IFRS. That is fully supported by the auditors, of course. Let me start by explaining the diagram on the left, where the bars represent net sales quarter by quarter. And then those consist of two things. One that we reference for product sales. There's a mix of deliveries to start, and secondly, the net profit share received from the startup. The second one is our licensing of products. That would be for this last quarter. It would be like the signing milestone payment for Valorem. And you can see how they differ. Then, if you overlay the line representing the gross margin, it becomes even more clear for an outsider, if I may say, which is driven by the deliveries we make to startups, selling products to the starter with serum margin, then receiving a net profit back. Additionally, the margin on those deliveries is then a net profit with marketing and sales expenses, already deducted, for this last quarter. The licensees quite often then deliver a gross margin of 100%. So the total revenues in the last quarter were 52 million. First of all, the net net profit from single was a rounded number of 22 million. And that was, as Martin said, driven by a very positive market mix, but also a positive gross margin impact. This is because the marketing and sales costs have now started to decline as both the volume and the sales are going up. Then, the license agreement, as I mentioned, was 27 million. And further on, we also had a positive COGS or cost of goods sold, driven very much by positive production variances, but also a retroactive adjustment from one major CMO, resulting in a price adjustment that will benefit our COGS moving forward. And you can also see the impact when we get to the balance sheet for accounts payable, because that was the resolution of a conflict that we had with the CMO. This meant that we held some payments in the AP area that are now resolved. We saw a somewhat readjusted COGS in the future. And we also see that this will actually result in a credit note in Q3. Looking at the cost side, you can see the administrative cost is starting to come down, partly because of the impact from the cost-saving scheme that we launched in November last year. However, we see a minor impact in Q2. That's because the majority of the positions leaving the company, now totaling 27 positions versus Q2 last year, left very late in March, meaning that this will then have full impact in March next year. But we're starting to see a positive impact. Last quarter we had approximately 5 million. Now we can see 11 million. Additionally, a further seven will resign during Q3. This means that 34 positions in total have left the company since June. Accounting for June in Q2, and then for the rest of the R&D section, as you can see, that's where the increase is noticeable. This is as we communicated and as expected, driven very much by the scale-up processes for both XTrain and EXP003. Uh, and so, that was expected. Yes, and also to agree the PFS, I should have mentioned the cash position. Uh, and you can see how we've tried to illustrate the movements from last quarter, starting with the 270 that we left off with in March. You can observe some significant moments. First of all, we have prepayments. That's the first of 66 coming in this quarter. That's part of our business as usual. So, we have an ongoing basis that consists of prepayments from the majority profit share. In this case, we see some VAT coming in from the UK and also from Lithuania. Second, we have production costs of around 50 million. And that's for the majority of this drug substance for the PFS, getting ready for the US. We have one, and the second is another product coming. And then, for allocating $40 million, that's again a payment to the CMO. The CMO is responsible for the scale-up processes in the experimental series of three, um, ten. And then you can also notice that we have $663 million. Sorry for the misinformation provided. We have 20 million going out for guarantors as part of the share mission. We have an organization which is 29 million, as you can see, a slight decrease already, as we mentioned, and then 29, resulting in 73. And with that, the cash and cash equivalents totaled $73 million, and the operating cash flow was approximately $100 million. And as mentioned, the majority is going to go ex-dividend in the quarter. And then we expect XRP 063 to scale up even more so in Q3, Q4. So, with that, back to the market.

Martin
25:35 - 27:37

Yeah, so to try to summarize them, as mentioned. Generated revenues of about 50 million Swedish crowns. It was a positive impact on the profit sharing from Silas, which was good news. And then the upfront payment, for US territory, from Belgium. Um, and, um, yeah. Progress in the commercialization of Ximluci across Europe was noted, with an increase in net sales during the quarter, which was positive. We received positive feedback from the EMA on the exchange program, which positions that program differently and significantly increases our possibilities to partner this program. Looking ahead to the third quarter, as you all have noticed from our recent press releases, our full focus is now on successfully licensing both Xtrain and Xbox Zero 3 in the coming months, ideally before October ends. As I've mentioned, we are running processes under an established timeline, which comes to an end in end of October. And we are optimistic that we're going to be able to achieve that. Given the current level of interest, we have high expectations. And then beyond that, of course, there are continued development activities for and other programs to maintain the pace in the respective programs. So that probably concludes the formal presentation. And I guess we can then open up for Q&A. So, we can first allow questions.

Operator
27:37 - 27:56

If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Philip Ineson from Red Eye. Please go ahead.

Philip Ineson
27:57 - 28:11

Hello, everybody, and thank you for taking my questions. I have just one query initially. Do you have any insights on where we stand right now concerning product sales so far into Q3?

Martin
28:14 - 28:37

No, not beyond that. The trend we've seen over the last couple of quarters is continuing where we are not seeing any changes from that trend. And as previously communicated and guided, we are expecting to see between 20 to 30% quarterly growth. And I think we're following that trajectory.

Philip Ineson
28:40 - 28:50

Okay, good. And for the second one, how would you advise us to look at the opex base moving forward here into H2?

Martin
28:52 - 28:53

I don't want to speculate.

Annette Lindquist
28:54 - 29:56

Yes. And thank you, Philip. And, obviously, just following the total opex gets a bit, you know, complicated because we have the savings as we just presented, and those were in the areas that we described last year. So the majority was salaries, personnel costs, and also consultants. And also then, you know, all other expenditures driven by personnel. We have had other things too, taking up a portion of the opex. We are continuing with the FDA process. We have then had some back charges and also from lawyers' costs resulting from the sharing mission. So just looking at the opex line shows us all savings are represented. It's very difficult to follow because some costs move upwards and some, downward. I think the alternative cost would be even higher if we hadn't done the savings, if you like.

Philip Ineson
30:00 - 30:27

Got it. So, a tricky question, but I know you are very busy with out-licensing processes, but in a scenario where these are not reached, how should we think about how much cash would potentially be needed until Q2 2025 when you think you will be cash flow positive from Chinook?

Martin
30:30 - 31:38

I think we, along with the board, are, as always, looking at different financing options for the business. And we continue to do so, although I think we communicated clearly that our main focus now is to successfully license these programs. And the upfront payments bridge from a financial perspective to Q2 2025. Now, when it comes to the financing gap to Q2 2025, well, I think we have some optionality, if you will, with regards to what we do and do not do. I think particularly when it comes to programs, if they are envisioned to continue at full pace or if they are discontinued in case of unsuccessful licensing. So there is some flexibility there. So I don't think we can come up with a firm number there now. It's just dependent on the strategy. In that case, we choose to deploy, particularly in relation to those two programs.

Philip Ineson
31:41 - 31:59

Right. And the last one related to the licensing processes. Which one would you say is the most likely to be licensed from where they stand right now? And also what sort of deal structure would be preferable?

Unknown 1
32:01 - 32:01

Um.

Martin
32:01 - 34:25

Yeah, I think they both are currently paused. I couldn't tell which one is most likely. We have the ambition to do both, and there are some counterparts we'll be talking to who are interested in both. So, that's our vision. It's hard to say otherwise. Which one is most likely to? To be our strength over time? But when it comes to the deal terms we are targeting, we are, of course, targeting an upfront contribution, which somehow reflects the investments we've made so far in the programs and the value of the programs, which should altogether bring us financially to Q2 next year. That's one thing we're trying to accomplish. The other thing we're trying to accomplish here is that the majority of the upcoming development expenditures should be carried by a partner, to limit our own. Yeah, we can undertake development responsibility. But from a financial perspective, we want to be cautious to undertake further commitments to invest in, for example, clinical trials and so on and so forth. And beyond those two points, we are trying to maximize the entire structure and particularly the back end, to get as much out of the final opportunities as possible, because we still believe very much in both of these programs. We believe they have very good potential. I mean, if you look at 'Ximluci', for example, it's targeting an originator product with expected sales of 14 billion US dollars by the time of loss of exclusivity. And given the size of that product, I would say there is rather limited expected biosimilar competition so far. And on '003', it is maybe the only one similar to originator drugs with an expected value of 2 billion US dollars. We believe a lot in the commercial potential of these products. And of course, we want to make sure that we get as much of that upside as possible.

Philip Ineson
34:27 - 34:29

Okay. That's helpful. Thank you.

Operator
34:33 - 34:53

As a reminder, if you wish to ask a question, please dial pound key five on your telephone keypad. There are no more phone questions at this time, so I hand the conference back to the speakers for any written questions and closing comments.

Annette Lindquist
34:55 - 36:42

So, thank you. Operator. Um, so, uh, then the first one is coming from Jen Lee. What are the measures that you can take to further reduce costs, and maybe if I kick off and say that, you know, a majority of our cost base is really related to kind of the three. Um, biosimilar candidates are often tied up by contractual obligations to contract manufacturers. That's really where the majority of the spend is. And we have ongoing negotiations with them on what we can phase differently, what we can move. So that is something that we have worked with, uh, for quite some time now. Uh, secondly, we are, as I mentioned, slowly moving on costs. And that is to reduce personnel-related costs in all aspects. We have introduced travel restrictions, educational restrictions. We are questioning every consultant and also that has moved our headcount target from 93 to 71 in total. Uh, so I think that we are all mindful, and I would like to emphasize that all our employees are behind us here, questioning whatever they can to reduce the cost base, and some impacts we get immediately and some areas are slightly slower, like rent, etc. Anything you would like to add there, Martin? No, the second one is also from the same, what is the progress of the prefilled syringe? And then I can tie that with the second question coming from Stefan Eriksen. When can we see a prefilled syringe both in the US and in Europe?

Martin
36:43 - 37:07

And I think that it's progressing according to plan. And, uh, we stick to the plan that the prefilled syringe could be or should be launched, uh, provided approval, of course, in Europe next year. And when it comes to the US, uh, we need to get back post expected approval for it in the US, Q2 next year. Then we need to get back on timing for the prefilled syringe launch.

Annette Lindquist
37:09 - 37:36

Then the last question from Jan Churn is around our confidence in outsourcing timing. And I think that we have alluded to or explored that earlier. So I'll move on to a question from Oscar. What is in the break clause with Biogen regarding XRP? CCR three. Could you explain if we will receive a further milestone payment from Biogen in relation to the successful scale-up of the drug substance, and how much could that payment be?

Martin
37:39 - 37:56

Yeah, this is a question I don't think we can or should comment on publicly. We are committed to following the agreement with Biogen, and we expect them to also follow the agreement. But more than that, I don't think we can comment at this stage.

Annette Lindquist
37:57 - 38:34

A question from Phillip addressed why the real reason was why Alorion terminated the contract. Additionally, the reason why Biogen chose to leave, and to also explain, is that this was meant to be. Beep 003 was so attractive, the newly built biosimilar now. Why did you decide to terminate such an attractive opportunity?

Unknown 1
38:36 - 38:37

Um.

Martin
38:38 - 41:18

I can start a little bit here. So if we start with Bausch and Lomb, this was now a while back. Um, and also you recall it, we had a webcast immediately after that news was released, and the feedback or information we got from Bausch at that stage was a strategic revision where they decided not to engage in biosimilars. They had a new CEO coming in, and they made the decision to focus solely on novel drugs and not to engage in biosimilars. At Biogen, the feedback we received from Bayer was that they have been trying to divest their biosimilar business for quite some time, I think probably 18 months or so. They were trying to publicly announce that they should divest the entire biosimilar business. In their earnings call related to the Q2 report this year, they communicated that they have decided to retain the biosimilar business. Hence, they were not successful in divesting it. One can conclude now that Bayern's core focus rests within a novel. Treatments for neurodegenerative disorders. And you've also been following some setbacks they've had in Europe for one of the lead assets. I think they also communicated in their earnings call that they have been going through a development spend prioritization exercise and a development spend reduction program. I think the communication from buying tasks was related to a strategic revision leading to the termination, but we at least read it in this context that the development spend needed to be directed towards the core business, and hence, the biosimilar business was not being considered a core part. Termination of this agreement came as a consequence. That's our interpretation of the rationale behind it, based on what was communicated to us.

Annette Lindquist
41:22 - 41:31

Okay. Actually, two related questions came from Dan and Oren. Say, what about Saudi Arabia and similar topics that had been mentioned earlier?

Martin
41:32 - 41:50

Yes, there are regulatory processes ongoing in several Middle Eastern countries. The dossier has been submitted to several authorities, and we expect the approvals and launches during 2025.

Annette Lindquist
41:53 - 42:07

And then, I think this is the last one, the round platform value. Is there something that we could explore with other big pharma either to sell or to utilize in any other shape or form?

Unknown 1
42:11 - 42:12

Um.

Martin
42:13 - 43:04

When it comes to the platform itself. As you know, it's focused on high-yield expression of proteins, either in E. coli or mammalian cells. Our prime focus has been to develop our own biosimilars based on that platform. We have those smaller engagements where, without licenses, certain IP rights are involved, and we are in discussions where we could be out-licensing IP for other programs. Um, and I see it continues continuing on.

Unknown 1
43:04 - 43:04

An.

Martin
43:04 - 43:30

Optimistic perspective. I think we need now to focus on monetizing our existing programs, essentially concentrating on the biosimilar segment. We're taking opportunities as they arise when it comes to further exploiting the platform.

Annette Lindquist
43:32 - 43:41

Uh, and then, uh, the last one is from Krystal Ferguson. Can you provide any updates on the FDA's perspective on an accelerated clinical development timeline?

Unknown 1
43:48 - 43:49

Um.

Martin
43:51 - 43:53

On accelerated clinical development.

Unknown 1
43:54 - 43:54

I'm not.

Annette Lindquist
43:54 - 43:58

Sure, what is it referring to?

Unknown 1
43:58 - 43:59

This, uh.

Martin
43:59 - 45:14

Referring to Ximluci, there is no further clinical development to be done for seamless transition, and there is a six-month review process for a resubmitted BLA as we discussed earlier, if that's what the question is about. Um, if we consider it more generally, this is about the guidelines for biosimilar development. As we have alluded to, our Xtrain program is now seeing an acceptance from regulatory authorities for a streamlined, reduced, or accelerated clinical development plan for biosimilars. So we see that happening now, and we're very glad to see that. Frankly speaking, it must happen for this industry to be sustainable and for allowing healthy competition for these respective biologic drugs, making them affordable post patent expiry. And I'm very glad to see that happening now, as we observe the regulatory authorities adopting such thinking.

Annette Lindquist
45:17 - 45:27

I think that concludes the questions. Uh, on, on, on, uh, in writing. Are there any other questions on the phone?

Martin
45:30 - 45:35

Bill, there's one question coming in here on the stock price.

Annette Lindquist
45:35 - 45:54

Okay, yes, that's from Philip. And it's also on the stock price. We went from 182 to 16. What's the plan to turn around the company? Is there any thoughts on inverted split? Um, so, yeah, sorry about that, Martin.

Martin
45:54 - 46:33

And. Yeah. And our focus is exactly on turning around the company and and the in now focus is to success. Apart from everything else we're doing successfully. License these two programs activated XP 003. In order to bridge the financials towards expected positive cash flow, uh, without, um, having to do any further dilutive, uh, financing. That's that's where our focus lies when it comes to, um, you know, share split and so on. Uh, we haven't discussed that, and it's something we will have to get back on.

Annette Lindquist
46:36 - 46:43

Another one coming in. Do you know what's biosimilar? Uh, what what biosimilars valorem have in oncology, if any.

Unknown 1
46:45 - 46:46

Um.

Martin
46:47 - 47:21

I don't think they've disclosed that. So I don't think we can disclose too much on that, but we can say that, um. They see similarities between oncology and ophthalmology. Uh, with regards to how these drugs are commercialized in, in the US, um, there are hospital dispensed and uh, um, and they see they see that they can do it in a different way. Uh, for biosimilars, both in oncology and ophthalmology. And hence they are very much focused on both these two, uh, therapeutic areas.

Annette Lindquist
47:25 - 47:30

Okay. So with that operator, anything from the, uh, from the audience.

Operator
47:31 - 47:34

We have no further questions on the phone line.

Unknown 1
47:38 - 47:38

Good.

Martin
47:38 - 47:56

Okay. And then I think we can conclude that this webcast and we thank you all who are listening and, um, asking questions and, uh, we're here. Should you have any follow up questions on that myself? So please reach out via email or phone. Thank you for that.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…